Skip to main content

Table 3 Changes of CRP, VEGF and RI

From: Efficacy of wIRA in the treatment of sacroiliitis in male patients with ankylosing spondylitis and its effect on serum VEGF levels

 

Before the first stage

After the first stage

After the second stage

CRP (mg/L)

 Treatment regimen A

30.21 ± 6.98

27.33 ± 6.23a

29.96 ± 6.21

 Treatment regimen B

30.03 ± 8.33

29.55 ± 7.71

26.83 ± 6.08

VEGF (pg/ml)

 Treatment regimen A

180.22 ± 18.51

178.32 ± 16.10b

179.63 ± 17.59

 Treatment regimen B

182.87 ± 23.31

183.12 ± 21.40c

180.45 ± 20.49

RI (0~1)

 Treatment regimen A

0.53 ± 0.05

0.85 ± 0.04d

0.63 ± 0.04

 Treatment regimen B

0.54 ± 0.05

0.55 ± 0.06

0.83 ± 0.04

  1. CRP C-reactive protein, VEGF vascular endothelial growth factor, RI resistance index
  2. aCompared with that before the first stage (P = 0.032)
  3. bCompared with that before the first stage (P = 0.230)
  4. cCompared with that before the first stage (P = 0.120)
  5. dCompared with that before the first stage (P < 0.001)
Back to article page

Journal of Orthopaedic Surgery and Research

ISSN: 1749-799X